TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intrapulmonary Percussive Ventilation and Nasal Continuous Positive Airway Pressure Ventilation in Transient Respiratory Distress of the Newborn: A Randomized Controlled Trial
Brief Summary: During caesarean section, transient respiratory distress which occurs frequently (3%) with possible complications are at present managed by non invasive nasal continuous positive airway pressure ventilation (nCPAP) associated with oxygen therapy. Intrapulmonary Percussive Ventilation (IPV) is a non-invasive ventilatory mode used in some intensive care units to treat some respiratory distress syndrome of the newborn with a good tolerance, but without evaluation in prospective studies


Options:
A: Arm Label: NHFOV; Type: EXPERIMENTAL; Interventions: Device: NHFOV | Arm Label: NCPAP; Type: ACTIVE_COMPARATOR; Interventions: Device: NCPAP | Arm Label: NIPPV; Type: EXPERIMENTAL; Interventions: Device: NIPPV | Intervention Type: DEVICE; Name: NHFOV; Assigned to Arm(s): NHFOV | Intervention Type: DEVICE; Name: NCPAP; Assigned to Arm(s): NCPAP | Intervention Type: DEVICE; Name: NIPPV; Assigned to Arm(s): NIPPV
B: Arm Label: NCPAP; Type: ACTIVE_COMPARATOR; Interventions: Procedure: infants receive primary non-invasive respiratory support by mean of nCPAP, Procedure: infants receive primary non-invasive respiratory support by mean of NHFOV | Arm Label: NHFOV; Type: ACTIVE_COMPARATOR; Interventions: Procedure: infants receive primary non-invasive respiratory support by mean of nCPAP, Procedure: infants receive primary non-invasive respiratory support by mean of NHFOV | Intervention Type: PROCEDURE; Name: infants receive primary non-invasive respiratory support by mean of nCPAP; Assigned to Arm(s): NCPAP, NHFOV | Intervention Type: PROCEDURE; Name: infants receive primary non-invasive respiratory support by mean of NHFOV; Assigned to Arm(s): NCPAP, NHFOV
C: Arm Label: nHFPV; Type: EXPERIMENTAL; Interventions: Procedure: Intrapulmonary Percussive Ventilation | Arm Label: nCPAP; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Nasal Continuous Positive Airway Pressure ventilation | Intervention Type: PROCEDURE; Name: Nasal Continuous Positive Airway Pressure ventilation; Assigned to Arm(s): nCPAP | Intervention Type: PROCEDURE; Name: Intrapulmonary Percussive Ventilation; Assigned to Arm(s): nHFPV
D: Arm Label: nHFOV; Type: EXPERIMENTAL; Interventions: Device: nHFOV | Arm Label: nCPAP; Type: ACTIVE_COMPARATOR; Interventions: Device: nCPAP | Intervention Type: DEVICE; Name: nHFOV; Assigned to Arm(s): nHFOV | Intervention Type: DEVICE; Name: nCPAP; Assigned to Arm(s): nCPAP

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intrapulmonary Percussive Ventilation and Nasal Continuous Positive Airway Pressure Ventilation in Transient Respiratory Distress of the Newborn: A Randomized Controlled Trial
Brief Summary: During caesarean section, transient respiratory distress which occurs frequently (3%) with possible complications are at present managed by non invasive nasal continuous positive airway pressure ventilation (nCPAP) associated with oxygen therapy. Intrapulmonary Percussive Ventilation (IPV) is a non-invasive ventilatory mode used in some intensive care units to treat some respiratory distress syndrome of the newborn with a good tolerance, but without evaluation in prospective studies


Options:
A: Arm Label: nHFPV; Type: EXPERIMENTAL; Interventions: Procedure: Intrapulmonary Percussive Ventilation | Arm Label: nCPAP; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Nasal Continuous Positive Airway Pressure ventilation | Intervention Type: PROCEDURE; Name: Nasal Continuous Positive Airway Pressure ventilation; Assigned to Arm(s): nCPAP | Intervention Type: PROCEDURE; Name: Intrapulmonary Percussive Ventilation; Assigned to Arm(s): nHFPV
B: Arm Label: Inhaled steroids (Budicort); Type: EXPERIMENTAL; Interventions: Drug: Experimental group: Budicort by Inhalation | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Experimental group: Budicort by Inhalation; Assigned to Arm(s): Inhaled steroids (Budicort) | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Control
C: Arm Label: Standard Fluids; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Restricted Fluids; Type: EXPERIMENTAL; Interventions: Other: Amount of total fluids | Intervention Type: OTHER; Name: Amount of total fluids; Assigned to Arm(s): Restricted Fluids
D: Arm Label: Neopuff group; Type: EXPERIMENTAL; Interventions: Device: Neopuff | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Neopuff; Assigned to Arm(s): Neopuff group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Fast Track in Open Colonic Surgery - A Multicentric Randomized Controlled Trial
Brief Summary: To investigate the real value of a fast track protocol compared to a standard care protocol regarding postoperative complications and hospital stay in a multicentric setting in an intention to treat fashion.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Fluid titrated with the use of arterial pulse contour cardiac output monitor if SVV >13% | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Fluid titrated at the discretion of the attending anesthesiologist | Intervention Type: OTHER; Name: Fluid titrated with the use of arterial pulse contour cardiac output monitor if SVV >13%; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Fluid titrated at the discretion of the attending anesthesiologist; Assigned to Arm(s): Control
B: Arm Label: 1; Type: OTHER; Interventions: Procedure: Standard Care | Arm Label: 2; Type: OTHER; Interventions: Procedure: Fast Track care | Intervention Type: PROCEDURE; Name: Standard Care; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Fast Track care; Assigned to Arm(s): 2
C: Arm Label: Automated fluid management system (Closed-loop system); Type: EXPERIMENTAL; Interventions: Device: Closed loop automated System (LIR®: learning intravenous resuscitator) | Arm Label: Current practice manual fluid management; Type: SHAM_COMPARATOR; Interventions: Device: manual current practice by anesthesiologist team | Intervention Type: DEVICE; Name: Closed loop automated System (LIR®: learning intravenous resuscitator); Assigned to Arm(s): Automated fluid management system (Closed-loop system) | Intervention Type: DEVICE; Name: manual current practice by anesthesiologist team; Assigned to Arm(s): Current practice manual fluid management
D: Arm Label: Closed-loop GDFT; Type: EXPERIMENTAL; Interventions: Device: Closed-Loop GDFT | Arm Label: Restrictive fluid therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Restrictive Fluid Therapy | Intervention Type: DEVICE; Name: Closed-Loop GDFT; Assigned to Arm(s): Closed-loop GDFT | Intervention Type: OTHER; Name: Restrictive Fluid Therapy; Assigned to Arm(s): Restrictive fluid therapy

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Fast Track in Open Colonic Surgery - A Multicentric Randomized Controlled Trial
Brief Summary: To investigate the real value of a fast track protocol compared to a standard care protocol regarding postoperative complications and hospital stay in a multicentric setting in an intention to treat fashion.


Options:
A: Arm Label: 1; Type: OTHER; Interventions: Procedure: Standard Care | Arm Label: 2; Type: OTHER; Interventions: Procedure: Fast Track care | Intervention Type: PROCEDURE; Name: Standard Care; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Fast Track care; Assigned to Arm(s): 2
B: Arm Label: Nutricia PreOp + Lipid; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Nutricia PreOp nutritional supplement, Dietary Supplement: Lipid | Arm Label: Nutrica PreOP + Glutamine; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Nutricia PreOp nutritional supplement, Dietary Supplement: Glutamine | Arm Label: Nutricia PreOP; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Nutricia PreOp nutritional supplement | Intervention Type: DIETARY_SUPPLEMENT; Name: Nutricia PreOp nutritional supplement; Assigned to Arm(s): Nutrica PreOP + Glutamine, Nutricia PreOP, Nutricia PreOp + Lipid | Intervention Type: DIETARY_SUPPLEMENT; Name: Lipid; Assigned to Arm(s): Nutricia PreOp + Lipid | Intervention Type: DIETARY_SUPPLEMENT; Name: Glutamine; Assigned to Arm(s): Nutrica PreOP + Glutamine
C: Arm Label: CHO; Type: EXPERIMENTAL; Interventions: Dietary Supplement: PreOp carbohydrate drink | Arm Label: FAST; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: PreOp carbohydrate drink; Assigned to Arm(s): CHO
D: Arm Label: Test; Type: EXPERIMENTAL; Interventions: Dietary Supplement: PreOP Booster (oral nutritional supplement, food for special medical purposes) | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: PreOP Booster (oral nutritional supplement, food for special medical purposes) | Intervention Type: DIETARY_SUPPLEMENT; Name: PreOP Booster (oral nutritional supplement, food for special medical purposes); Assigned to Arm(s): Control, Test

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Hip Fracture Evaluation With Alternatives of Total Hip Arthroplasty Versus Hemi-Arthroplasty: A Multi-Centre Randomized Trial Comparing Total Hip Arthroplasty and Hemi-Arthroplasty on Secondary Procedures and Quality of Life in Patients With Displaced Femoral Neck Fractures
Brief Summary: Each year, hip fracture, an injury that can impair independence and quality of life, occurs in about 280,000 Americans and 36,000 Canadians. By the year 2040, the annual healthcare costs associated with hip fractures are expected to reach $9.8 billion in the United States and $650 million in Canada. It is important to have in place optimal practice guidelines for the surgical handling of this injury. One type of hip fracture, called a displaced femoral neck fracture, is often treated with a hip replacement surgery. Patients undergoing a hip replacement may receive either a total hip replacement, in which the head of the femur and the hip joint socket are replaced, or a partial hip replacement, in which only the head of the femur is replaced. This study will compare the two different hip replacement procedures to determine which one results in better outcomes after surgery in adults aged 50 and older.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Device: Dual mobility cup | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Device: Standard cup | Intervention Type: DEVICE; Name: Dual mobility cup; Assigned to Arm(s): Intervention | Intervention Type: DEVICE; Name: Standard cup; Assigned to Arm(s): Control
B: Arm Label: Gamma nail, fracture stabilization, better walking; Type: ACTIVE_COMPARATOR; Interventions: Device: gamma nail stryker | Intervention Type: DEVICE; Name: gamma nail stryker; Assigned to Arm(s): Gamma nail, fracture stabilization, better walking
C: Arm Label: Cemented femoral stem; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Cemented femoral stem | Arm Label: Uncemented femoral stem; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Uncemented femoral stem | Intervention Type: PROCEDURE; Name: Uncemented femoral stem; Assigned to Arm(s): Uncemented femoral stem | Intervention Type: PROCEDURE; Name: Cemented femoral stem; Assigned to Arm(s): Cemented femoral stem
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: Total hip arthroplasty | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Hemi-arthroplasty | Intervention Type: DEVICE; Name: Total hip arthroplasty; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: Hemi-arthroplasty; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Hip Fracture Evaluation With Alternatives of Total Hip Arthroplasty Versus Hemi-Arthroplasty: A Multi-Centre Randomized Trial Comparing Total Hip Arthroplasty and Hemi-Arthroplasty on Secondary Procedures and Quality of Life in Patients With Displaced Femoral Neck Fractures
Brief Summary: Each year, hip fracture, an injury that can impair independence and quality of life, occurs in about 280,000 Americans and 36,000 Canadians. By the year 2040, the annual healthcare costs associated with hip fractures are expected to reach $9.8 billion in the United States and $650 million in Canada. It is important to have in place optimal practice guidelines for the surgical handling of this injury. One type of hip fracture, called a displaced femoral neck fracture, is often treated with a hip replacement surgery. Patients undergoing a hip replacement may receive either a total hip replacement, in which the head of the femur and the hip joint socket are replaced, or a partial hip replacement, in which only the head of the femur is replaced. This study will compare the two different hip replacement procedures to determine which one results in better outcomes after surgery in adults aged 50 and older.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: Total hip arthroplasty | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Hemi-arthroplasty | Intervention Type: DEVICE; Name: Total hip arthroplasty; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: Hemi-arthroplasty; Assigned to Arm(s): 2
B: Intervention Type: PROCEDURE; Name: Bipolar hemiarthroplasty (Charnley/Hastings); Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Internal fixation with two parallel screws (Olmed); Assigned to Arm(s): N/A
C: Arm Label: Single Sliding Hip Screw; Type: EXPERIMENTAL; Interventions: Device: Open reduction internal fixation (ORIF) with single sliding hip screw | Arm Label: Multiple Cancellous Screws; Type: EXPERIMENTAL; Interventions: Device: ORIF with multiple cancellous screws | Intervention Type: DEVICE; Name: Open reduction internal fixation (ORIF) with single sliding hip screw; Assigned to Arm(s): Single Sliding Hip Screw | Intervention Type: DEVICE; Name: ORIF with multiple cancellous screws; Assigned to Arm(s): Multiple Cancellous Screws
D: Arm Label: Conservative Treatment for Impacted Femoral Neck Fracture; Type: EXPERIMENTAL; Interventions: Procedure: Surgical Treatment for Impacted Femoral Neck Fracture | Intervention Type: PROCEDURE; Name: Surgical Treatment for Impacted Femoral Neck Fracture; Assigned to Arm(s): Conservative Treatment for Impacted Femoral Neck Fracture

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Placebo-controlled Trial on the Effect of rhDNase on Ventilation Inhomogeneity in Patients With Cystic Fibrosis
Brief Summary: This study will assess whether rhDNase treatment improves ventilation inhomogeneity as assessed by lung clearance index (LCI) in patients with cystic fibrosis (CF).


Options:
A: Arm Label: USUAL CARE; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: INHALATION WITH PEP DEVICE; Type: ACTIVE_COMPARATOR; Interventions: Device: INHALATION WITH PEP DEVICE (Acapella Duet) | Intervention Type: DEVICE; Name: INHALATION WITH PEP DEVICE (Acapella Duet); Assigned to Arm(s): INHALATION WITH PEP DEVICE
B: Arm Label: 1; Type: OTHER; Interventions: Drug: rhDNAse, Other: Placebo | Arm Label: 2; Type: OTHER; Interventions: Drug: rhDNAse, Other: Placebo | Intervention Type: DRUG; Name: rhDNAse; Assigned to Arm(s): 1, 2 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 1, 2
C: Arm Label: Active Treatment Group; Type: EXPERIMENTAL; Interventions: Drug: Active Treatment Group 7% Hypertonic Saline | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Control Group 0.9% Isotonic Saline | Intervention Type: DRUG; Name: Active Treatment Group 7% Hypertonic Saline; Assigned to Arm(s): Active Treatment Group | Intervention Type: DRUG; Name: Control Group 0.9% Isotonic Saline; Assigned to Arm(s): Control Group
D: Arm Label: Master Study Run-in; Type: N/A; Interventions: N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Placebo-controlled Trial on the Effect of rhDNase on Ventilation Inhomogeneity in Patients With Cystic Fibrosis
Brief Summary: This study will assess whether rhDNase treatment improves ventilation inhomogeneity as assessed by lung clearance index (LCI) in patients with cystic fibrosis (CF).


Options:
A: Arm Label: 1; Type: OTHER; Interventions: Drug: rhDNAse, Other: Placebo | Arm Label: 2; Type: OTHER; Interventions: Drug: rhDNAse, Other: Placebo | Intervention Type: DRUG; Name: rhDNAse; Assigned to Arm(s): 1, 2 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 1, 2
B: Arm Label: Dornase alfa; Type: EXPERIMENTAL; Interventions: Drug: Dornase alfa (Pulmozyme), Drug: isotonic saline | Arm Label: isotonic saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Dornase alfa (Pulmozyme), Drug: isotonic saline | Intervention Type: DRUG; Name: Dornase alfa (Pulmozyme); Assigned to Arm(s): Dornase alfa, isotonic saline | Intervention Type: DRUG; Name: isotonic saline; Assigned to Arm(s): Dornase alfa, isotonic saline
C: Arm Label: eRapid Nebulizer; Type: EXPERIMENTAL; Interventions: Drug: dornase alfa [Pulmozyme®] | Arm Label: Jet Nebulizer; Type: ACTIVE_COMPARATOR; Interventions: Drug: dornase alfa [Pulmozyme®] | Intervention Type: DRUG; Name: dornase alfa [Pulmozyme®]; Assigned to Arm(s): eRapid Nebulizer | Intervention Type: DRUG; Name: dornase alfa [Pulmozyme®]; Assigned to Arm(s): Jet Nebulizer
D: Intervention Type: DRUG; Name: Inhaled mannitol; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Placebo-controlled Trial on the Effect of rhDNase on Ventilation Inhomogeneity in Patients With Cystic Fibrosis
Brief Summary: This study will assess whether rhDNase treatment improves ventilation inhomogeneity as assessed by lung clearance index (LCI) in patients with cystic fibrosis (CF).


Options:
A: Arm Label: Dornase alfa; Type: EXPERIMENTAL; Interventions: Drug: Dornase alfa (Pulmozyme), Drug: isotonic saline | Arm Label: isotonic saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Dornase alfa (Pulmozyme), Drug: isotonic saline | Intervention Type: DRUG; Name: Dornase alfa (Pulmozyme); Assigned to Arm(s): Dornase alfa, isotonic saline | Intervention Type: DRUG; Name: isotonic saline; Assigned to Arm(s): Dornase alfa, isotonic saline
B: Arm Label: 1; Type: OTHER; Interventions: Drug: rhDNAse, Other: Placebo | Arm Label: 2; Type: OTHER; Interventions: Drug: rhDNAse, Other: Placebo | Intervention Type: DRUG; Name: rhDNAse; Assigned to Arm(s): 1, 2 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 1, 2
C: Arm Label: eRapid Nebulizer; Type: EXPERIMENTAL; Interventions: Drug: dornase alfa [Pulmozyme®] | Arm Label: Jet Nebulizer; Type: ACTIVE_COMPARATOR; Interventions: Drug: dornase alfa [Pulmozyme®] | Intervention Type: DRUG; Name: dornase alfa [Pulmozyme®]; Assigned to Arm(s): eRapid Nebulizer | Intervention Type: DRUG; Name: dornase alfa [Pulmozyme®]; Assigned to Arm(s): Jet Nebulizer
D: Intervention Type: DRUG; Name: Inhaled mannitol; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early Pulmonary Rehabilitation (PR) Following Hospitalisation For Acute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)
Brief Summary: The principal aim of the study is to evaluate whether attendance at an exercise training and education programme (known as pulmonary rehabilitation) shortly following hospital discharge can lead to a reduction in exacerbations and improvement in exercise capacity and quality of life in patients with chronic obstructive pulmonary disease.


Options:
A: Arm Label: Activity-Self Management; Type: EXPERIMENTAL; Interventions: Behavioral: Self-Management and Motivational Interviewing | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Self-Management and Motivational Interviewing; Assigned to Arm(s): Activity-Self Management
B: Arm Label: resistance training; Type: EXPERIMENTAL; Interventions: Other: Resistance training | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Resistance training; Assigned to Arm(s): resistance training
C: Arm Label: comprehensive care programme; Type: ACTIVE_COMPARATOR; Interventions: Other: Comprehensive care programme | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Comprehensive care programme; Assigned to Arm(s): comprehensive care programme
D: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: EPR; Type: EXPERIMENTAL; Interventions: Other: Early pulmonary rehabilitation (EPR) | Intervention Type: OTHER; Name: Early pulmonary rehabilitation (EPR); Assigned to Arm(s): EPR

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Parallel Comparison of Tenofovir and Emtricitabine/Tenofovir Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples
Brief Summary: Randomized, blinded, placebo-controlled trial to demonstrate if pre-exposure prophylaxis decreases HIV-1 acquisition among HIV-1 uninfected individuals within HIV-1 discordant couples.


Options:
A: Arm Label: TDF-FTC,condoms,adh/risk counseling; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg | Arm Label: Placebo,condoms,adh/risk counseling; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Oral Tablet | Intervention Type: DRUG; Name: Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg; Assigned to Arm(s): TDF-FTC,condoms,adh/risk counseling | Intervention Type: DRUG; Name: Placebo Oral Tablet; Assigned to Arm(s): Placebo,condoms,adh/risk counseling
B: Arm Label: TDF/FTC; Type: EXPERIMENTAL; Interventions: Drug: daily TDF/FTC | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: daily TDF/FTC; Assigned to Arm(s): TDF/FTC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Truvada Arm; Type: EXPERIMENTAL; Interventions: Drug: Truvada | Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Truvada; Assigned to Arm(s): Truvada Arm | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo Arm
D: Arm Label: Tenofovir Disoproxil Fumarate (TDF); Type: ACTIVE_COMPARATOR; Interventions: Drug: Tenofovir Disoproxil Fumarate (TDF) | Arm Label: Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF); Type: ACTIVE_COMPARATOR; Interventions: Drug: Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tenofovir Disoproxil Fumarate (TDF); Assigned to Arm(s): Tenofovir Disoproxil Fumarate (TDF) | Intervention Type: DRUG; Name: Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF); Assigned to Arm(s): Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D